BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
France Targets Shein, Temu With Fast-Fashion Fees 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
OpenAI Rejects Apple Trade Secret Theft Claims 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Add as a preferred source on Google
BURLINGTON, Mass., March 19, 2018 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial Operations, will participate in a fireside chat at Needham & Company's 17th Annual Healthcare Conference in New York City on Tuesday, March 27, 2018 at 10 a.m. ET. To access the live webcast and subsequent archived recording of the presentation, visit the Flexion website at http://ir.flexiontherapeutics.com.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Flexion was named one of The Boston Business Journal's 2017 Best Places to Work and one of the Top Places to Work in Massachusetts by The Boston Globe.
Contact:
Scott Young
Vice President, Corporate Communications and Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
[email protected]
